NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,561,396 | +198.9% | 1,706,588 | +668.0% | 0.14% | +209.1% |
| Q2 2023 | $9,221,591 | +1317.4% | 222,207 | +1954.0% | 0.04% | +1366.7% |
| Q1 2023 | $650,595 | -85.1% | 10,818 | -82.8% | 0.00% | -87.0% |
| Q2 2022 | $4,366,000 | +28.4% | 62,818 | +53.1% | 0.02% | +21.1% |
| Q1 2022 | $3,400,000 | -2.7% | 41,038 | -11.8% | 0.02% | 0.0% |
| Q4 2021 | $3,493,000 | -36.0% | 46,518 | +89.1% | 0.02% | -50.0% |
| Q2 2021 | $5,457,000 | -82.3% | 24,599 | -89.5% | 0.04% | -83.2% |
| Q1 2021 | $30,895,000 | +0.9% | 233,734 | +32.1% | 0.23% | -12.1% |
| Q4 2020 | $30,608,000 | +238.3% | 176,883 | +117.6% | 0.26% | +242.7% |
| Q3 2020 | $9,047,000 | +250.3% | 81,277 | +86.6% | 0.08% | +150.0% |
| Q2 2020 | $2,583,000 | -14.0% | 43,550 | +8.4% | 0.03% | -42.3% |
| Q3 2019 | $3,004,000 | +62.7% | 40,173 | +37.6% | 0.05% | +2.0% |
| Q2 2019 | $1,846,000 | -34.4% | 29,199 | -50.0% | 0.05% | -40.0% |
| Q1 2019 | $2,812,000 | -8.6% | 58,386 | -40.6% | 0.08% | +3.7% |
| Q2 2018 | $3,076,000 | – | 98,290 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $24,386,000 | 14.72% |
| HARTLINE INVESTMENT CORP/ | 335,191 | $58,001,000 | 8.32% |
| Deep Track Capital, LP | 1,341,300 | $93,220,000 | 6.13% |
| MORGAN JESS S & CO INC | 48,345 | $3,360,000 | 3.48% |
| Taylor Frigon Capital Management LLC | 68,908 | $4,789,000 | 2.49% |
| HighVista Strategies LLC | 28,007 | $1,946,000 | 1.18% |
| Private Harbour Investment Management & Counsel, LLC | 13,106 | $911,000 | 1.01% |
| Lloyd Park, LLC | 9,325 | $648,000 | 0.68% |
| Baillie Gifford | 9,116,230 | $633,578,000 | 0.65% |
| HAP Trading, LLC | 110,900 | $10,575,000 | 0.53% |